TISIDB

Summary
Symbol	PLXNA4
Name	plexin A4
Aliases	KIAA1550; DKFZp434G0625PRO34003; FAYV2820; PLXNA4A; PLXNA4B; plexin A4, A; plexin A4, B; PLEXA4A; PRO34003; ......
Chromosomal Location	7q32.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell membrane Single-pass type I membrane protein
Domain	PF08337 Plexin cytoplasmic RasGAP domain PF01437 Plexin repeat PF01403 Sema domain PF01833 IPT/TIG domain
Function	Coreceptor for SEMA3A. Necessary for signaling by class 3 semaphorins and subsequent remodeling of the cytoskeleton. Plays a role in axon guidance in the developing nervous system. Class 3 semaphorins bind to a complex composed of a neuropilin and a plexin. The plexin modulates the affinity of the complex for specific semaphorins, and its cytoplasmic domain is required for the activation of down-stream signaling events in the cytoplasm (By similarity).

> Gene Ontology [ TOP ]
Biological Process	GO:0001558 regulation of cell growth GO:0007409 axonogenesis GO:0007411 axon guidance GO:0007422 peripheral nervous system development GO:0008045 motor neuron axon guidance GO:0008361 regulation of cell size GO:0010769 regulation of cell morphogenesis involved in differentiation GO:0010975 regulation of neuron projection development GO:0016049 cell growth GO:0021537 telencephalon development GO:0021545 cranial nerve development GO:0021559 trigeminal nerve development GO:0021561 facial nerve development GO:0021563 glossopharyngeal nerve development GO:0021564 vagus nerve development GO:0021602 cranial nerve morphogenesis GO:0021604 cranial nerve structural organization GO:0021610 facial nerve morphogenesis GO:0021612 facial nerve structural organization GO:0021615 glossopharyngeal nerve morphogenesis GO:0021636 trigeminal nerve morphogenesis GO:0021637 trigeminal nerve structural organization GO:0021644 vagus nerve morphogenesis GO:0021675 nerve development GO:0021783 preganglionic parasympathetic fiber development GO:0021784 postganglionic parasympathetic fiber development GO:0021785 branchiomotor neuron axon guidance GO:0021793 chemorepulsion of branchiomotor axon GO:0021952 central nervous system projection neuron axonogenesis GO:0021953 central nervous system neuron differentiation GO:0021954 central nervous system neuron development GO:0021955 central nervous system neuron axonogenesis GO:0021960 anterior commissure morphogenesis GO:0022604 regulation of cell morphogenesis GO:0030516 regulation of axon extension GO:0030900 forebrain development GO:0032535 regulation of cellular component size GO:0048483 autonomic nervous system development GO:0048485 sympathetic nervous system development GO:0048486 parasympathetic nervous system development GO:0048532 anatomical structure arrangement GO:0048588 developmental cell growth GO:0048638 regulation of developmental growth GO:0048667 cell morphogenesis involved in neuron differentiation GO:0048675 axon extension GO:0048841 regulation of axon extension involved in axon guidance GO:0048846 axon extension involved in axon guidance GO:0050770 regulation of axonogenesis GO:0050919 negative chemotaxis GO:0050920 regulation of chemotaxis GO:0050923 regulation of negative chemotaxis GO:0060560 developmental growth involved in morphogenesis GO:0061387 regulation of extent of cell growth GO:0061564 axon development GO:0061643 chemorepulsion of axon GO:0071526 semaphorin-plexin signaling pathway GO:0090066 regulation of anatomical structure size GO:0097485 neuron projection guidance GO:1902284 neuron projection extension involved in neuron projection guidance GO:1902285 semaphorin-plexin signaling pathway involved in neuron projection guidance GO:1902287 semaphorin-plexin signaling pathway involved in axon guidance GO:1902667 regulation of axon guidance GO:1990138 neuron projection extension
Molecular Function	GO:0017154 semaphorin receptor activity
Cellular Component	GO:0002116 semaphorin receptor complex GO:0043235 receptor complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04360 Axon guidance
Reactome	R-HSA-422475: Axon guidance R-HSA-399956: CRMPs in Sema3A signaling R-HSA-1266738: Developmental Biology R-HSA-416700: Other semaphorin interactions R-HSA-399955: SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion R-HSA-399954: Sema3A PAK dependent Axon repulsion R-HSA-373755: Semaphorin interactions

Summary
Symbol	PLXNA4
Name	plexin A4
Aliases	KIAA1550; DKFZp434G0625PRO34003; FAYV2820; PLXNA4A; PLXNA4B; plexin A4, A; plexin A4, B; PLEXA4A; PRO34003; ......
Chromosomal Location	7q32.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between PLXNA4 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	PLXNA4
Name	plexin A4
Aliases	KIAA1550; DKFZp434G0625PRO34003; FAYV2820; PLXNA4A; PLXNA4B; plexin A4, A; plexin A4, B; PLEXA4A; PRO34003; ......
Chromosomal Location	7q32.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of PLXNA4 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	PLXNA4
Name	plexin A4
Aliases	KIAA1550; DKFZp434G0625PRO34003; FAYV2820; PLXNA4A; PLXNA4B; plexin A4, A; plexin A4, B; PLEXA4A; PRO34003; ......
Chromosomal Location	7q32.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of PLXNA4 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.37	0.334
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.383	0.555
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.367	0.494
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.533	0.267
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.663	0.682
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.368	0.856
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.326	0.636
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.749	0.484
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.04	0.971
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.762	0.315
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.172	0.861
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.496	0.064

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of PLXNA4 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	17.6	-17.6	0.232
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	33.3	-33.3	0.231
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	14.3	-14.3	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	25.9	2.7	23.2	0.00131
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	25.9	3.4	22.5	0.0036
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	14.3	41.2	-26.9	0.078
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	25	33.3	-8.3	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	45.5	-37.8	0.0608
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	22.2	6.2	16	0.53
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	40	11.1	28.9	0.505
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	7.9	3.7	4.2	0.636
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	13.6	0	13.6	0.279
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	7.1	-7.1	0.467
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	PLXNA4
Name	plexin A4
Aliases	KIAA1550; DKFZp434G0625PRO34003; FAYV2820; PLXNA4A; PLXNA4B; plexin A4, A; plexin A4, B; PLEXA4A; PRO34003; ......
Chromosomal Location	7q32.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PLXNA4. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	PLXNA4
Name	plexin A4
Aliases	KIAA1550; DKFZp434G0625PRO34003; FAYV2820; PLXNA4A; PLXNA4B; plexin A4, A; plexin A4, B; PLEXA4A; PRO34003; ......
Chromosomal Location	7q32.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PLXNA4. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PLXNA4. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	PLXNA4
Name	plexin A4
Aliases	KIAA1550; DKFZp434G0625PRO34003; FAYV2820; PLXNA4A; PLXNA4B; plexin A4, A; plexin A4, B; PLEXA4A; PRO34003; ......
Chromosomal Location	7q32.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PLXNA4. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	PLXNA4
Name	plexin A4
Aliases	KIAA1550; DKFZp434G0625PRO34003; FAYV2820; PLXNA4A; PLXNA4B; plexin A4, A; plexin A4, B; PLEXA4A; PRO34003; ......
Chromosomal Location	7q32.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of PLXNA4 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	PLXNA4
Name	plexin A4
Aliases	KIAA1550; DKFZp434G0625PRO34003; FAYV2820; PLXNA4A; PLXNA4B; plexin A4, A; plexin A4, B; PLEXA4A; PRO34003; ......
Chromosomal Location	7q32.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between PLXNA4 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	PLXNA4
Name	plexin A4
Aliases	KIAA1550; DKFZp434G0625PRO34003; FAYV2820; PLXNA4A; PLXNA4B; plexin A4, A; plexin A4, B; PLEXA4A; PRO34003; ......
Chromosomal Location	7q32.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting PLXNA4 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse PLXNA4